BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 15072561)

  • 1. Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens.
    Margueron R; Duong V; Bonnet S; Escande A; Vignon F; Balaguer P; Cavaillès V
    J Mol Endocrinol; 2004 Apr; 32(2):583-94. PubMed ID: 15072561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
    Long X; Fan M; Bigsby RM; Nephew KP
    Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells.
    Dardes RC; Schafer JM; Pearce ST; Osipo C; Chen B; Jordan VC
    Gynecol Oncol; 2002 Jun; 85(3):498-506. PubMed ID: 12051881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of UDP-glucuronosyltransferase 2B15 gene expression by the major active metabolites of tamoxifen, 4-hydroxytamoxifen and endoxifen, in breast cancer cells.
    Chanawong A; Hu DG; Meech R; Mackenzie PI; McKinnon RA
    Drug Metab Dispos; 2015 Jun; 43(6):889-97. PubMed ID: 25795461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
    Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
    Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.
    Long X; Fan M; Nephew KP
    Cancer Biol Ther; 2010 Mar; 9(5):389-96. PubMed ID: 20061804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of coregulators influenced by estrogen receptor subtype specific binding of the ER antagonists 4-hydroxytamoxifen and fulvestrant.
    Evers NM; Wang S; van den Berg JH; Houtman R; Melchers D; de Haan LH; Ederveen AG; Groten JP; Rietjens IM
    Chem Biol Interact; 2014 Sep; 220():222-30. PubMed ID: 25014417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of estradiol and selective estrogen receptor modulators in the mouse N20.1 oligodendrocyte/astrocytes cell line.
    Guzmán CB; Deighton-Collins S; Martinez A; Kleerekoper M; Zhao C; Benjamins JA; Skafar DF
    Neuro Endocrinol Lett; 2005 Oct; 26(5):526-32. PubMed ID: 16264406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oestrogen receptors pathways to oestrogen responsive elements: the transactivation function-1 acts as the keystone of oestrogen receptor (ER)beta-mediated transcriptional repression of ERalpha.
    Gougelet A; Mueller SO; Korach KS; Renoir JM
    J Steroid Biochem Mol Biol; 2007 May; 104(3-5):110-22. PubMed ID: 17478088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.
    Jang ER; Lim SJ; Lee ES; Jeong G; Kim TY; Bang YJ; Lee JS
    Oncogene; 2004 Mar; 23(9):1724-36. PubMed ID: 14676837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor β expression.
    Tu Z; Li H; Ma Y; Tang B; Tian J; Akers W; Achilefu S; Gu Y
    Mol Cell Biochem; 2012 Jul; 366(1-2):111-22. PubMed ID: 22476901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines.
    Alao JP; Lam EW; Ali S; Buluwela L; Bordogna W; Lockey P; Varshochi R; Stavropoulou AV; Coombes RC; Vigushin DM
    Clin Cancer Res; 2004 Dec; 10(23):8094-104. PubMed ID: 15585645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells.
    Kim K; Thu N; Saville B; Safe S
    Mol Endocrinol; 2003 May; 17(5):804-17. PubMed ID: 12576490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen response element-dependent regulation of transcriptional activation of estrogen receptors alpha and beta by coactivators and corepressors.
    Klinge CM; Jernigan SC; Mattingly KA; Risinger KE; Zhang J
    J Mol Endocrinol; 2004 Oct; 33(2):387-410. PubMed ID: 15525597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of estrogenic/antiestrogenic activity of Onobrychis ebenoides extract - interaction with estrogen receptor subtypes ERalpha and ERbeta.
    Papoutsi Z; Kassi E; Halabalaki M; Mitakou S; Moutsatsou P
    Toxicol In Vitro; 2007 Apr; 21(3):364-70. PubMed ID: 17092687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.
    Fiskus W; Ren Y; Mohapatra A; Bali P; Mandawat A; Rao R; Herger B; Yang Y; Atadja P; Wu J; Bhalla K
    Clin Cancer Res; 2007 Aug; 13(16):4882-90. PubMed ID: 17699868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage.
    Bianco NR; Perry G; Smith MA; Templeton DJ; Montano MM
    Mol Endocrinol; 2003 Jul; 17(7):1344-55. PubMed ID: 12714703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The AF-2 cofactor binding region is key for the selective SUMOylation of estrogen receptor alpha by antiestrogens.
    Vallet A; El Ezzy M; Diennet M; Haidar S; Bouvier M; Mader S
    J Biol Chem; 2023 Jan; 299(1):102757. PubMed ID: 36460099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen.
    Wu X; Subramaniam M; Grygo SB; Sun Z; Negron V; Lingle WL; Goetz MP; Ingle JN; Spelsberg TC; Hawse JR
    Breast Cancer Res; 2011 Mar; 13(2):R27. PubMed ID: 21392396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.
    Yang X; Phillips DL; Ferguson AT; Nelson WG; Herman JG; Davidson NE
    Cancer Res; 2001 Oct; 61(19):7025-9. PubMed ID: 11585728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.